ProCE Banner Activity

NeoTRIPaPDL1 Michelangelo: Neoadjuvant Chemotherapy ± Atezolizumab in Early, High-Risk and Locally Advanced TNBC

Slideset Download
Conference Coverage
No significant increase in pCR rate with addition of atezolizumab to carboplatin/nab-paclitaxel in women with early, high-risk and locally advanced TNBC.

Share

Provided by

Provided by Clinical Care Options, LLC.
ProCE Banner

Supporters

Supported by educational grants from

Daiichi Sankyo, Inc.

Genentech TEXT Only

Merck Sharp & Dohme Corp.

Puma Biotechnology, Inc.

Seagen